Wuxi Bio announced that the company noted that a procedural ...

Wuxi Bio announced that the company noted that a procedural hearing about a revised draft bill was held by the U.S. Senate.
Wuxi Bio's share price extended further decline to 21% in HK in the afternoon session.
The company reiterated that it is not a subsidiary of WUXI Apptec and does not have a human genomics business, nor does it collect human genomic data in any of its businesses.